@nntaleb Surely part of you always doubted that the side who holds all the power and with fanatics in leadership roles would have no interest in compromising with the other side who also has fanatics in leadership roles.
@MosabHasanYOSEF I wonder if many of these Nobel laureates you are referring to are wishing for an enlightened nation like Israel to figure out a more enlightened way of battling Hamas? More pagers less carpet bombing.
@Vik_deshpandeMD Are there any good examples of successfully addressing dx inequities? It’s important to point them out but even more important to have solutions.
April #ASCOPlenarySeries to highlight:
⭐ Interim EFS analysis of ph3 Neotorch: Perioperative toripalimab + platinum-doublet chemo for #NSCLC
⭐ KRYSTAL-1: Adagrasib in adv solid tumors w KRASG12C mutation
📅 Live presentation 4/20 @ 3 PM ET
Details: https://t.co/DQOZADGB8p
NCCN Adds Mirati Therapeutics' Krazati to Guidelines for KRAS-Mutant NSCLC With Brain Metastases. The guidelines suggest Krazati as a systemic therapy option for patients with KRAS G12C-mutant non-small cell lung cancer with central nervous system... https://t.co/n2g0PepWEj
TRACK is a National precision medicine study for rare cancers. Target Cancer and Foundation Medicine partnered to make this decentralised study. Very proud to serve as PI.